Quest for the right Drug
סרטייד דיסקוס 50/250 מק"ג SERETIDE DISKUS 50/250 MCG (FLUTICASONE PROPIONATE, SALMETEROL AS XINAFOATE)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
שאיפה : INHALATION
צורת מינון:
אבקה לשאיפה : POWDER FOR INHALATION
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Adverse reactions : תופעות לוואי
4.8 Undesirable effects As Seretide contains salmeterol and fluticasone propionate, the type and severity of adverse reactions associated with each of the compounds may be expected. There is no incidence of additional adverse events following concurrent administration of the two compounds. Adverse events which have been associated with salmeterol/fluticasone propionate are given below, listed by system organ class and frequency. Frequencies are defined as: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1000 to <1/100), rare (≥1/10,000 to <1/1000) and not known (cannot be estimated from the available data). Frequencies were derived from clinical trial data. The incidence in placebo was not taken into account. System Organ Class Adverse Event Frequency Infections & Candidiasis of the mouth and throat Common Infestations Pneumonia (in COPD patients) Common1,3,5 Bronchitis Common1,3 Oesophageal candidiasis Rare Immune System Hypersensitivity reactions with the following Disorders manifestations: Cutaneous hypersensitivity reactions Uncommon Angioedema (mainly facial and oropharyngeal Rare oedema) Respiratory symptoms (dyspnoea) Uncommon Respiratory symptoms (bronchospasm) Rare Anaphylactic reactions including anaphylactic shock Rare System Organ Class Adverse Event Frequency Endocrine Disorders Cushing’s syndrome, Cushingoid features, Adrenal Rare4 suppression, Growth retardation in children and adolescents, Decreased bone mineral density Metabolism & Hypokalaemia Common3 Nutrition Disorders Hyperglycaemia Uncommon4 Psychiatric Disorders Anxiety Uncommon Sleep disorders Uncommon Behavioural changes, including psychomotor Rare hyperactivity and irritability (predominantly in children) Depression, aggression (predominantly in children) Not known Nervous System Headache Very Common1 Disorders Tremor Uncommon Eye Disorders Cataract Uncommon Glaucoma Rare4 Vision, blurred Not known4 Cardiac Disorders Palpitations Uncommon Tachycardia Uncommon Cardiac arrhythmias (including supraventricular Rare tachycardia and extrasystoles). Atrial fibrillation Uncommon Angina pectoris Uncommon Respiratory, Thoracic Nasopharyngitis Very Common2,3 & Mediastinal Disorders Throat irritation Common Hoarseness/dysphonia Common Sinusitis Common1,3 Paradoxical bronchospasm Rare4 Skin and Contusions Common1,3 subcutaneous tissue disorders System Organ Class Adverse Event Frequency Musculoskeletal & Muscle cramps Common Connective Tissue Disorders Traumatic fractures Common1,3 Arthralgia Common Myalgia Common 1. Reported commonly in placebo 2. Reported very commonly in placebo 3. Reported over 3 years in a COPD study 4. See section 4.4 5. See section 5.1. Description of selected adverse reactions The pharmacological side effects of β2 agonist treatment, such as tremor, palpitations and headache, have been reported, but tend to be transient and reduce with regular therapy. As with other inhalation therapy paradoxical bronchospasm may occur with an immediate increase in wheezing and shortness of breath after dosing. Paradoxical bronchospasm responds to a rapid-acting bronchodilator and should be treated straightaway. Seretide Diskus should be discontinued immediately, the patient assessed and alternative therapy instituted if necessary. Due to the fluticasone propionate component, hoarseness and candidiasis (thrush) of the mouth and throat and, rarely, of the oesophagus can occur in some patients. Both hoarseness and incidence of mouth and throat candidiasis may be relieved by rinsing the mouth with water and/or brushing the teeth after using the product. Symptomatic mouth and throat candidiasis can be treated with topical anti-fungal therapy whilst still continuing with the Seretide Diskus. Paediatric population Possible systemic effects include Cushing’s syndrome, Cushingoid features, adrenal suppression and growth retardation in children and adolescents (see section 4.4). Children may also experience anxiety, sleep disorders and behavioural changes, including hyperactivity and irritability. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form https://sideeffects.health.gov.il/. Additionally, you should also report to GSK Israel (il.safety@gsk.com)
מסגרת הכללה בסל
התוויות הכלולות במסגרת הסל
התוויה | תאריך הכללה | תחום קליני | Class Effect | מצב מחלה |
---|---|---|---|---|
COPD | ||||
אסטמה |
שימוש לפי פנקס קופ''ח כללית 1994
לא צוין
תאריך הכללה מקורי בסל
01/03/2008
הגבלות
תרופה מוגבלת לרישום ע'י רופא מומחה או הגבלה אחרת
מידע נוסף